Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amiloride in primary hyperaldosteronism

G T Griffing, A G Cole, S A Aurecchia

    Clinical Pharmacology and Therapeutics
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Roll-your-own tobacco use among Canadian youth: current prevalence and changes in youth smoking "rollies" since 2008.

    Chronic diseases and injuries in Canada·2014
    Same author

    Therapy of adrenocortical cancer with o,p' DDD in two children.

    The Journal of clinical endocrinology and metabolism·2014
    Same author

    Minimizing pharmacodynamic interactions of high doses of lacosamide.

    Acta neurologica Scandinavica·2011
    Same author

    A review of diversity in the evolution and development of cartilage: the search for the origin of the chondrocyte.

    European cells & materials·2011
    Same author

    Fluorescent in situ hybridization reveals multiple expression domains for SpBrn1/2/4 and identifies a unique ectodermal cell type that co-expresses the ParaHox gene SpLox.

    Gene expression patterns : GEP·2009
    Same author

    Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia.

    Journal of endocrinological investigation·2003
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Amiloride effectively treats low potassium (hypokalemia) and high blood pressure in primary hyperaldosteronism. This study shows amiloride improves potassium levels and lowers blood pressure in patients with this condition.

    Area of Science:

    • Endocrinology
    • Nephrology
    • Pharmacology

    Background:

    • Primary hyperaldosteronism causes hypertension and hypokalemia.
    • Amiloride is a potassium-sparing diuretic.
    • The efficacy of amiloride in primary hyperaldosteronism requires further investigation.

    Purpose of the Study:

    • To evaluate the effects of amiloride on plasma potassium levels and blood pressure in patients with primary hyperaldosteronism.
    • To assess the safety and tolerability of amiloride in this patient population.

    Main Methods:

    • Prospective study of 12 patients with primary hyperaldosteronism.
    • Patients received amiloride (10-40 mg daily) for 6 months.
    • Plasma potassium levels and blood pressure were monitored.

    Related Experiment Videos

    Main Results:

    • Amiloride significantly increased plasma potassium levels (0.96 mEq/l, P < 0.001).
    • Mean blood pressure decreased by 22/10 mm Hg (P < 0.001).
    • No significant adverse events were attributed to amiloride.

    Conclusions:

    • Amiloride is effective in correcting hypokalemia in primary hyperaldosteronism.
    • Amiloride helps ameliorate hypertension in primary hyperaldosteronism, often requiring additional antihypertensive therapy.
    • Amiloride is well-tolerated in patients with primary hyperaldosteronism.